Array BioPharma
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
01History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.
In November 2000, the company became a public company via an initial public offering.
In June 2019, Pfizer acquired the company for approximately $11 billion.
02Discovery of FDA Approved Small Molecules
- MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
- TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
- BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
- KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
- KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
- VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)
- RETEVMO (Selpercatinib) - RET inhibitor - Approved 2024, licensed by Loxo Oncology (Eli Lilly)
- GANOVO (Danoprevir) - HCV Protease inhibitor - Approved 2018 (in China), licensed by Roche
Sources and credits
This article is adapted from the Wikipedia article “Array BioPharma”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.